The lengthy synthetic peptide-based cancer vaccine (SVX vaccine) targeting surviving TAA was created and studied by Onodi et al. It has three distinct peptides that represent CD4+ and CD8+ epitopes that bind to HLA-1 and HLA-2 components. Here, CD8A is linked to cancer.